Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

Table 3 Baseline values and changes in efficacy parameters

Parameter	Baseline	Week 12	Week 24
Glandular function tests
Schirmer's test (millimeters per 5 minutes)	2.0 ± 3.2	3.4 ± 3.5	4.4 ± 4.9
Whole saliva (grams per 5 minutes)	0.49 ± 0.41	0.48 ± 0.41	0.56 ± 0.41
Laboratory tests
Erythrocyte sedimentation rate (mm/hour)	47.6 ± 20.5	44.1 ± 23.3	44.2 ± 21.0
Gamma globulins (g/L)	21.3 ± 6.3	19.5 ± 8.6^a	18.8 ± 7.5^b
IgG (mg/dL)	2,159 ± 949	2,048 ± 755	2,025 ± 895
IgM (mg/dL)	189 ± 108	144 ± 62.7^a	142 ± 62.8^a
IgA (mg/dL)	399 ± 417	359 ± 363	329 ± 305
Rheumatoid factor IgM (IU/mL)	275 ± 504	193 ± 380	179 ± 317^a
Anti-SSA antibodies (U/mL)	5,863 ± 5,321	6,308 ± 4,008	5,892 ± 8,859
Anti-SSB antibodies (U/mL)	1,217 ± 1,386	1,424 ± 1,925	1,320 ± 1,668
C3 (mg/dL)	99.3 ± 30.2	101 ± 33.5	108 ± 34.7^b
C4 (mg/dL)	14.9 ± 8.8	16.4 ± 9.5^a	16.8 ± 8.9^b
Subjective findings
VAS sicca syndrome (0 to 100 mm)	68.7 ± 15.6	56.4 ± 19.9	52.8 ± 20.8^a
VAS arthralgia (0 to 100 mm)	62.1 ± 23.4	45.1 ± 34.3	47.5 ± 30.0
VAS fatigue (0 to 100 mm)	63.4 ± 24.0	57.4 ± 33.4	65.3 ± 22.6
Use of artificial teardrops (times per day)	3.7 ± 2.3	1.8 ± 1.3^a	1.6 ± 1.9^b
Health Assessment Questionnaire score	0.73 ± 0.77	0.81 ± 0.84	0.73 ± 0.80

^ap < 0.05 versus baseline value analyzed by Wilcoxon signed rank test; ^bp < 0.02 versus baseline value analyzed by Wilcoxon signed rank test. Table presents outcome parameters in the eight patients with primary Sjögren syndrome who completed the study. Data are presented as mean ± standard deviation. Ig, immunoglobulin; VAS, visual analogue scale.

ISSN: 1478-6362